메뉴 건너뛰기




Volumn , Issue 29, 2014, Pages 9862-9871

Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer

Author keywords

Colorectal cancer; Combinational therapy; Epidermal growth factor receptor; K ras mutation; Resistance

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BGT226; CETUXIMAB; COBIMETINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PILARALISIB; PIMASERTIB; PROTEIN KINASE B; RAS PROTEIN; RDEA119; RO5126766; SELUMETINIB; SORAFENIB; TAK 733; TRAMETINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB; XL 281; XL 765; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN INHIBITOR; RAF PROTEIN; RAS PROTEIN INHIBITOR; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

EID: 84905866650     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i29.9862     Document Type: Review
Times cited : (24)

References (99)
  • 1
    • 84890213381 scopus 로고    scopus 로고
    • Personalizing therapy for colorectal cancer
    • PMID: 24025538
    • Wong A, Ma BB. Personalizing therapy for colorectal cancer. Clin Gastroenterol Hepatol 2014; 12: 139-144 [PMID: 24025538 DOI: 10.1016/j.cgh.2013.08.040]
    • (2014) Clin Gastroenterol Hepatol , vol.12 , pp. 139-144
    • Wong, A.1    Ma, B.B.2
  • 2
    • 13744260035 scopus 로고    scopus 로고
    • Colorectal cancer prevention
    • PMID: 15637400
    • Hawk ET, Levin B. Colorectal cancer prevention. J Clin Oncol 2005; 23: 378-391 [PMID: 15637400 DOI: 10.1200/JCO.2005.08.097]
    • (2005) J Clin Oncol , vol.23 , pp. 378-391
    • Hawk, E.T.1    Levin, B.2
  • 3
    • 36949009111 scopus 로고    scopus 로고
    • Survival update and prognostic factor analysis of oxaliplatin (Ox) and irinotecan (Iri) combinations for metastatic colorectal cancer (MCRC)
    • Sanoff HK, Sargent SD, Campbell ME. Survival update and prognostic factor analysis of oxaliplatin (Ox) and irinotecan (Iri) combinations for metastatic colorectal cancer (MCRC). J Clin Oncol 2007; 25: 4067
    • (2007) J Clin Oncol , vol.25 , pp. 4067
    • Sanoff, H.K.1    Sargent, S.D.2    Campbell, M.E.3
  • 5
    • 34547979071 scopus 로고    scopus 로고
    • Metastatic colorectal cancer-past, progress and future
    • PMID: 17657834
    • Field K, Lipton L. Metastatic colorectal cancer-past, progress and future. World J Gastroenterol 2007; 13: 3806-3815 [PMID: 17657834]
    • (2007) World J Gastroenterol , vol.13 , pp. 3806-3815
    • Field, K.1    Lipton, L.2
  • 6
    • 0026721532 scopus 로고
    • Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
    • Advanced Colorectal Cancer Meta-Analysis Project. [PMID: 1534121]
    • Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992; 10: 896-903 [PMID: 1534121]
    • (1992) J Clin Oncol , vol.10 , pp. 896-903
  • 9
    • 1842569206 scopus 로고    scopus 로고
    • A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
    • PMID: 14665611
    • Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30 [PMID: 14665611 DOI: 10.1200/JCO.2004.09.046]
    • (2004) J Clin Oncol , vol.22 , pp. 23-30
    • Goldberg, R.M.1    Sargent, D.J.2    Morton, R.F.3    Fuchs, C.S.4    Ramanathan, R.K.5    Williamson, S.K.6    Findlay, B.P.7    Pitot, H.C.8    Alberts, S.R.9
  • 10
    • 2142703727 scopus 로고    scopus 로고
    • Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
    • PMID: 15051767
    • Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214 [PMID: 15051767 DOI: 10.1200/JCO.2004.11.037]
    • (2004) J Clin Oncol , vol.22 , pp. 1209-1214
    • Grothey, A.1    Sargent, D.2    Goldberg, R.M.3    Schmoll, H.J.4
  • 11
    • 0024580013 scopus 로고
    • Side effects and emotional distress during cancer chemotherapy
    • PMID: 2912536
    • Love RR, Leventhal H, Easterling DV, Nerenz DR. Side effects and emotional distress during cancer chemotherapy. Cancer 1989; 63: 604-612 [PMID: 2912536]
    • (1989) Cancer , vol.63 , pp. 604-612
    • Love, R.R.1    Leventhal, H.2    Easterling, D.V.3    Nerenz, D.R.4
  • 13
    • 33745828702 scopus 로고    scopus 로고
    • EGF-ERBB signalling: Towards the systems level
    • PMID: 16829981
    • Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-516 [PMID: 16829981 DOI: 10.1038/nrm1962]
    • (2006) Nat Rev Mol Cell Biol , vol.7 , pp. 505-516
    • Citri, A.1    Yarden, Y.2
  • 14
    • 44949238064 scopus 로고    scopus 로고
    • Current status of biomarkers in head and neck cancer
    • PMID: 18493942
    • Chang SS, Califano J. Current status of biomarkers in head and neck cancer. J Surg Oncol 2008; 97: 640-643 [PMID: 18493942 DOI: 10.1002/jso.21023]
    • (2008) J Surg Oncol , vol.97 , pp. 640-643
    • Chang, S.S.1    Califano, J.2
  • 15
    • 14644445166 scopus 로고    scopus 로고
    • Epidermal growth factor receptor signaling in colorectal cancer: Preclinical data and therapeutic perspectives
    • PMID: 15668269
    • Spano JP, Fagard R, Soria JC, Rixe O, Khayat D, Milano G. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol 2005; 16: 189-194 [PMID: 15668269 DOI: 10.1093/annonc/mdi057]
    • (2005) Ann Oncol , vol.16 , pp. 189-194
    • Spano, J.P.1    Fagard, R.2    Soria, J.C.3    Rixe, O.4    Khayat, D.5    Milano, G.6
  • 16
    • 84874167463 scopus 로고    scopus 로고
    • EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: A systematic review and meta analysis
    • PMID: 23441167
    • Jiang Z, Li C, Li F, Wang X. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis. PLoS One 2013; 8: e56205 [PMID: 23441167 DOI: 10.1371/journal.pone.0056205]
    • (2013) PLoS One , vol.8 , pp. e56205
    • Jiang, Z.1    Li, C.2    Li, F.3    Wang, X.4
  • 18
    • 0034778447 scopus 로고    scopus 로고
    • EGFR and cancer prognosis
    • PMID: 11597399
    • Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 Suppl 4: S9-15 [PMID: 11597399]
    • (2001) Eur J Cancer , vol.37 , pp. S9-S15
    • Nicholson, R.I.1    Gee, J.M.2    Harper, M.E.3
  • 19
    • 2142641698 scopus 로고    scopus 로고
    • Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
    • PMID: 14993230
    • Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208 [PMID: 14993230 DOI: 10.1200/JCO.2004.10.182]
    • (2004) J Clin Oncol , vol.22 , pp. 1201-1208
    • Saltz, L.B.1    Meropol, N.J.2    Loehrer, P.J.3    Needle, M.N.4    Kopit, J.5    Mayer, R.J.6
  • 21
    • 13744251436 scopus 로고    scopus 로고
    • Systemic therapy for colorectal cancer
    • PMID: 15689586
    • Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-487 [PMID: 15689586 DOI: 10.1056/NEJMra040958]
    • (2005) N Engl J Med , vol.352 , pp. 476-487
    • Meyerhardt, J.A.1    Mayer, R.J.2
  • 22
    • 34147103678 scopus 로고    scopus 로고
    • Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
    • PMID: 17470858
    • Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664 [PMID: 17470858 DOI: 10.1200/JCO.2006.08.1620]
    • (2007) J Clin Oncol , vol.25 , pp. 1658-1664
    • Van Cutsem, E.1    Peeters, M.2    Siena, S.3    Humblet, Y.4    Hendlisz, A.5    Neyns, B.6    Canon, J.L.7    Van Laethem, J.L.8    Maurel, J.9    Richardson, G.10    Wolf, M.11    Amado, R.G.12
  • 23
    • 84880825213 scopus 로고    scopus 로고
    • Information Fl
    • Information Fl. FDA labelling information. Available from: URL: http://www.fda.gov/cder/foi/label/2004/125084lbl.pdf
    • FDA Labelling Information
  • 25
    • 84880825213 scopus 로고    scopus 로고
    • FDA labelling information. Available from: URL: http://www.fda.gov/cder/foi/label/2006/125147s0000lbl.pdf
    • FDA Labelling Information
  • 27
    • 77951862140 scopus 로고    scopus 로고
    • Market watch: Emerging companion diagnostics for cancer drugs
    • PMID: 20431558
    • August J. Market watch: emerging companion diagnostics for cancer drugs. Nat Rev Drug Discov 2010; 9: 351 [PMID: 20431558 DOI: 10.1038/nrd3173]
    • (2010) Nat Rev Drug Discov , vol.9 , pp. 351
    • August, J.1
  • 29
    • 77949435827 scopus 로고    scopus 로고
    • Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer
    • PMID: 20100961
    • Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28: 1254-1261 [PMID: 20100961 DOI: 10.1200/JCO.2009.24.6116]
    • (2010) J Clin Oncol , vol.28 , pp. 1254-1261
    • Bardelli, A.1    Siena, S.2
  • 30
    • 0024376173 scopus 로고
    • ras oncogenes in human cancer: A review
    • PMID: 2547513
    • Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689 [PMID: 2547513]
    • (1989) Cancer Res , vol.49 , pp. 4682-4689
    • Bos, J.L.1
  • 31
    • 34047248571 scopus 로고    scopus 로고
    • Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
    • PMID: 17363584
    • Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67: 2643-2648 [PMID: 17363584 DOI: 10.1158/0008-5472.CAN-06-4158]
    • (2007) Cancer Res , vol.67 , pp. 2643-2648
    • Benvenuti, S.1    Sartore-Bianchi, A.2    Di Nicolantonio, F.3    Zanon, C.4    Moroni, M.5    Veronese, S.6    Siena, S.7    Bardelli, A.8
  • 33
    • 70349939382 scopus 로고    scopus 로고
    • Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer
    • PMID: 19738166
    • Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101: 1308-1324 [PMID: 19738166 DOI: 10.1093/jnci/djp280]
    • (2009) J Natl Cancer Inst , vol.101 , pp. 1308-1324
    • Siena, S.1    Sartore-Bianchi, A.2    Di Nicolantonio, F.3    Balfour, J.4    Bardelli, A.5
  • 36
    • 84875742535 scopus 로고    scopus 로고
    • Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: Assessment as prognostic and predictive biomarkers of response to panitumumab
    • PMID: 23182985
    • Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, Wiezorek J. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013; 31: 759-765 [PMID: 23182985 DOI: 10.1200/JCO.2012.45.1492]
    • (2013) J Clin Oncol , vol.31 , pp. 759-765
    • Peeters, M.1    Douillard, J.Y.2    Van Cutsem, E.3    Siena, S.4    Zhang, K.5    Williams, R.6    Wiezorek, J.7
  • 41
    • 18044387648 scopus 로고    scopus 로고
    • Raf kinase as a target for anticancer therapeutics
    • PMID: 15827342
    • Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 2005; 4: 677-685 [PMID: 15827342 DOI: 10.1158/1535-7163.MCT-04-0297]
    • (2005) Mol Cancer Ther , vol.4 , pp. 677-685
    • Sridhar, S.S.1    Hedley, D.2    Siu, L.L.3
  • 46
    • 0036632368 scopus 로고    scopus 로고
    • The phosphatidylinositol 3-Kinase AKT pathway in human cancer
    • PMID: 12094235
    • Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501 [PMID: 12094235 DOI: 10.1038/nrc839]
    • (2002) Nat Rev Cancer , vol.2 , pp. 489-501
    • Vivanco, I.1    Sawyers, C.L.2
  • 49
    • 40649096375 scopus 로고    scopus 로고
    • Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
    • PMID: 18268322
    • Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 2008; 105: 2652-2657 [PMID: 18268322 DOI: 10.1073/pnas.0712169105]
    • (2008) Proc Natl Acad Sci USA , vol.105 , pp. 2652-2657
    • Zhao, L.1    Vogt, P.K.2
  • 53
    • 84877946281 scopus 로고    scopus 로고
    • Sorafenib and everolimus in advanced clear cell renal carcinoma: A phase I/II trial of the SCRI Oncology Research Consortium
    • PMID: 23614653
    • Hainsworth JD, Waterhouse DM, Penley WC, Shipley DL, Thompson DS, Webb CD, Anthony Greco F. Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium. Cancer Invest 2013; 31: 323-329 [PMID: 23614653 DOI: 10.3109/07357907.2013.789900]
    • (2013) Cancer Invest , vol.31 , pp. 323-329
    • Hainsworth, J.D.1    Waterhouse, D.M.2    Penley, W.C.3    Shipley, D.L.4    Thompson, D.S.5    Webb, C.D.6    Anthony Greco, F.7
  • 54
    • 84881137155 scopus 로고    scopus 로고
    • Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens
    • PMID: 23743569
    • Ng K, Tabernero J, Hwang J, Bajetta E, Sharma S, Del Prete SA, Arrowsmith ER, Ryan DP, Sedova M, Jin J, Malek K, Fuchs CS. Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. Clin Cancer Res 2013; 19: 3987-3995 [PMID: 23743569 DOI: 10.1158/1078-0432.CCR-13-0027]
    • (2013) Clin Cancer Res , vol.19 , pp. 3987-3995
    • Ng, K.1    Tabernero, J.2    Hwang, J.3    Bajetta, E.4    Sharma, S.5    Del Prete, S.A.6    Arrowsmith, E.R.7    Ryan, D.P.8    Sedova, M.9    Jin, J.10    Malek, K.11    Fuchs, C.S.12
  • 55
    • 34748821802 scopus 로고    scopus 로고
    • The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion
    • PMID: 17766837
    • Hjelmeland AB, Lattimore KP, Fee BE, Shi Q, Wickman S, Keir ST, Hjelmeland MD, Batt D, Bigner DD, Friedman HS, Rich JN. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Mol Cancer Ther 2007; 6: 2449-2457 [PMID: 17766837 DOI: 10.1158/1535-7163.MCT-07-0155]
    • (2007) Mol Cancer Ther , vol.6 , pp. 2449-2457
    • Hjelmeland, A.B.1    Lattimore, K.P.2    Fee, B.E.3    Shi, Q.4    Wickman, S.5    Keir, S.T.6    Hjelmeland, M.D.7    Batt, D.8    Bigner, D.D.9    Friedman, H.S.10    Rich, J.N.11
  • 56
    • 79956018943 scopus 로고    scopus 로고
    • Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo
    • PMID: 21523318
    • Yamaguchi T, Kakefuda R, Tajima N, Sowa Y, Sakai T. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol 2011; 39: 23-31 [PMID: 21523318 DOI: 10.3892/ijo.2011.1015]
    • (2011) Int J Oncol , vol.39 , pp. 23-31
    • Yamaguchi, T.1    Kakefuda, R.2    Tajima, N.3    Sowa, Y.4    Sakai, T.5
  • 57
    • 84883490437 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors
    • PMID: 23860959
    • Honda K, Yamamoto N, Nokihara H, Tamura Y, Asahina H, Yamada Y, Suzuki S, Yamazaki N, Ogita Y, Tamura T. Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2013; 72: 577-584 [PMID: 23860959 DOI: 10.1007/s00280-013-2228-4]
    • (2013) Cancer Chemother Pharmacol , vol.72 , pp. 577-584
    • Honda, K.1    Yamamoto, N.2    Nokihara, H.3    Tamura, Y.4    Asahina, H.5    Yamada, Y.6    Suzuki, S.7    Yamazaki, N.8    Ogita, Y.9    Tamura, T.10
  • 61
    • 84865562515 scopus 로고    scopus 로고
    • Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
    • PMID: 22357447
    • Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, Mita M, Melendez Cuero M, Stutvoet S, Birle D, Anak O, Hackl W, Baselga J. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol 2012; 23: 2399-2408 [PMID: 22357447 DOI: 10.1093/annonc/mds011]
    • (2012) Ann Oncol , vol.23 , pp. 2399-2408
    • Markman, B.1    Tabernero, J.2    Krop, I.3    Shapiro, G.I.4    Siu, L.5    Chen, L.C.6    Mita, M.7    Melendez Cuero, M.8    Stutvoet, S.9    Birle, D.10    Anak, O.11    Hackl, W.12    Baselga, J.13
  • 64
    • 65649120430 scopus 로고    scopus 로고
    • In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase
    • PMID: 19366835
    • Chung EJ, Brown AP, Asano H, Mandler M, Burgan WE, Carter D, Camphausen K, Citrin D. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Clin Cancer Res 2009; 15: 3050-3057 [PMID: 19366835 DOI: 10.1158/1078-0432.CCR-08-2954]
    • (2009) Clin Cancer Res , vol.15 , pp. 3050-3057
    • Chung, E.J.1    Brown, A.P.2    Asano, H.3    Mandler, M.4    Burgan, W.E.5    Carter, D.6    Camphausen, K.7    Citrin, D.8
  • 65
    • 84855487013 scopus 로고    scopus 로고
    • A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
    • PMID: 20127139
    • Bennouna J, Lang I, Valladares-Ayerbes M, Boer K, Adenis A, Escudero P, Kim TY, Pover GM, Morris CD, Douillard JY. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs 2011; 29: 1021-1028 [PMID: 20127139 DOI: 10.1007/s10637-010-9392-8]
    • (2011) Invest New Drugs , vol.29 , pp. 1021-1028
    • Bennouna, J.1    Lang, I.2    Valladares-Ayerbes, M.3    Boer, K.4    Adenis, A.5    Escudero, P.6    Kim, T.Y.7    Pover, G.M.8    Morris, C.D.9    Douillard, J.Y.10
  • 66
    • 40749124035 scopus 로고    scopus 로고
    • The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel
    • PMID: 18172275
    • Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KS. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008; 14: 230-239 [PMID: 18172275 DOI: 10.1158/1078-0432.CCR-07-1440]
    • (2008) Clin Cancer Res , vol.14 , pp. 230-239
    • Haass, N.K.1    Sproesser, K.2    Nguyen, T.K.3    Contractor, R.4    Medina, C.A.5    Nathanson, K.L.6    Herlyn, M.7    Smalley, K.S.8
  • 70
    • 68849091778 scopus 로고    scopus 로고
    • NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
    • PMID: 19671762
    • Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevrria C, Yung WK. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 2009; 8: 2204-2210 [PMID: 19671762 DOI: 10.1158/1535-7163.MCT-09-0160]
    • (2009) Mol Cancer Ther , vol.8 , pp. 2204-2210
    • Liu, T.J.1    Koul, D.2    LaFortune, T.3    Tiao, N.4    Shen, R.J.5    Maira, S.M.6    Garcia-Echevrria, C.7    Yung, W.K.8
  • 72
    • 34748840281 scopus 로고    scopus 로고
    • The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures
    • PMID: 17766839
    • Howes AL, Chiang GG, Lang ES, Ho CB, Powis G, Vuori K, Abraham RT. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther 2007; 6: 2505-2514 [PMID: 17766839 DOI: 10.1158/1535-7163.MCT-06-0698]
    • (2007) Mol Cancer Ther , vol.6 , pp. 2505-2514
    • Howes, A.L.1    Chiang, G.G.2    Lang, E.S.3    Ho, C.B.4    Powis, G.5    Vuori, K.6    Abraham, R.T.7
  • 74
    • 62549160588 scopus 로고    scopus 로고
    • First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American society of clinical oncology meeting
    • PMID: 18959794
    • Molckovsky A, Siu LL. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol 2008; 1: 20 [PMID: 18959794 DOI: 10.1186/1756-8722-1-20]
    • (2008) J Hematol Oncol , vol.1 , pp. 20
    • Molckovsky, A.1    Siu, L.L.2
  • 75
    • 47249097988 scopus 로고    scopus 로고
    • BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells
    • PMID: 18458053
    • Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008; 6: 751-759 [PMID: 18458053 DOI: 10.1158/1541-7786.MCR-07-2001]
    • (2008) Mol Cancer Res , vol.6 , pp. 751-759
    • Sala, E.1    Mologni, L.2    Truffa, S.3    Gaetano, C.4    Bollag, G.E.5    Gambacorti-Passerini, C.6
  • 78
    • 79957523828 scopus 로고    scopus 로고
    • KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer
    • PMID: 21163703
    • De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12: 594-603 [PMID: 21163703 DOI: 10.1016/S1470-2045(10)70209-6]
    • (2011) Lancet Oncol , vol.12 , pp. 594-603
    • De Roock, W.1    De Vriendt, V.2    Normanno, N.3    Ciardiello, F.4    Tejpar, S.5
  • 81
    • 23844517889 scopus 로고    scopus 로고
    • A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study
    • PMID: 16133800
    • Macdonald JS, McCoy S, Whitehead RP, Iqbal S, Wade JL, Giguere JK, Abbruzzese JL. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs 2005; 23: 485-487 [PMID: 16133800 DOI: 10.1007/s10637-005-2908-y]
    • (2005) Invest New Drugs , vol.23 , pp. 485-487
    • Macdonald, J.S.1    McCoy, S.2    Whitehead, R.P.3    Iqbal, S.4    Wade, J.L.5    Giguere, J.K.6    Abbruzzese, J.L.7
  • 82
    • 0037932865 scopus 로고    scopus 로고
    • Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells
    • PMID: 12676586
    • Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003; 3: 285-296 [PMID: 12676586]
    • (2003) Cancer Cell , vol.3 , pp. 285-296
    • Dolma, S.1    Lessnick, S.L.2    Hahn, W.C.3    Stockwell, B.R.4
  • 83
    • 54749152429 scopus 로고    scopus 로고
    • Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota
    • PMID: 18794128
    • Guo W, Wu S, Liu J, Fang B. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res 2008; 68: 7403-7408 [PMID: 18794128 DOI: 10.1158/0008-5472.CAN-08-1449]
    • (2008) Cancer Res , vol.68 , pp. 7403-7408
    • Guo, W.1    Wu, S.2    Liu, J.3    Fang, B.4
  • 84
    • 0034795339 scopus 로고    scopus 로고
    • Use of isogenic human cancer cells for high-throughput screening and drug discovery
    • PMID: 11581659
    • Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol 2001; 19: 940-945 [PMID: 11581659 DOI: 10.1038/nbt1001-940]
    • (2001) Nat Biotechnol , vol.19 , pp. 940-945
    • Torrance, C.J.1    Agrawal, V.2    Vogelstein, B.3    Kinzler, K.W.4
  • 88
    • 77955918876 scopus 로고    scopus 로고
    • Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells
    • PMID: 20562906
    • Wang Y, Ngo VN, Marani M, Yang Y, Wright G, Staudt LM, Downward J. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 2010; 29: 4658-4670 [PMID: 20562906 DOI: 10.1038/onc.2010.218]
    • (2010) Oncogene , vol.29 , pp. 4658-4670
    • Wang, Y.1    Ngo, V.N.2    Marani, M.3    Yang, Y.4    Wright, G.5    Staudt, L.M.6    Downward, J.7
  • 89
    • 66149091940 scopus 로고    scopus 로고
    • A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene
    • PMID: 19490893
    • Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009; 137: 835-848 [PMID: 19490893 DOI: 10.1016/j.cell.2009.05.006]
    • (2009) Cell , vol.137 , pp. 835-848
    • Luo, J.1    Emanuele, M.J.2    Li, D.3    Creighton, C.J.4    Schlabach, M.R.5    Westbrook, T.F.6    Wong, K.K.7    Elledge, S.J.8
  • 92
    • 84876758394 scopus 로고    scopus 로고
    • BRAF inhibitors in clinical oncology
    • PMID: 23585929
    • Morris V, Kopetz S. BRAF inhibitors in clinical oncology. F1000Prime Rep 2013; 5: 11 [PMID: 23585929 DOI: 10.12703/P5-11]
    • (2013) F1000Prime Rep , vol.5 , pp. 11
    • Morris, V.1    Kopetz, S.2
  • 94
    • 78751480476 scopus 로고    scopus 로고
    • MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy
    • PMID: 21118963
    • Yoon J, Koo KH, Choi KY. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res 2011; 71: 445-453 [PMID: 21118963 DOI: 10.1158/0008-5472.CAN-10-3058]
    • (2011) Cancer Res , vol.71 , pp. 445-453
    • Yoon, J.1    Koo, K.H.2    Choi, K.Y.3
  • 96
    • 66249116702 scopus 로고    scopus 로고
    • PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers
    • PMID: 19401449
    • Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009; 69: 4286-4293 [PMID: 19401449 DOI: 10.1158/0008-5472.CAN-08-4765]
    • (2009) Cancer Res , vol.69 , pp. 4286-4293
    • Wee, S.1    Jagani, Z.2    Xiang, K.X.3    Loo, A.4    Dorsch, M.5    Yao, Y.M.6    Sellers, W.R.7    Lengauer, C.8    Stegmeier, F.9
  • 97
    • 63349097231 scopus 로고    scopus 로고
    • Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer
    • PMID: 19194827
    • Zhang YJ, Tian XQ, Sun DF, Zhao SL, Xiong H, Fang JY. Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer. Cancer Invest 2009; 27: 273-285 [PMID: 19194827 DOI: 10.1080/07357900802314893]
    • (2009) Cancer Invest , vol.27 , pp. 273-285
    • Zhang, Y.J.1    Tian, X.Q.2    Sun, D.F.3    Zhao, S.L.4    Xiong, H.5    Fang, J.Y.6
  • 99
    • 79959594837 scopus 로고    scopus 로고
    • Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance
    • PMID: 21738740
    • Oikonomou E, Koc M, Sourkova V, Andera L, Pintzas A. Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PLoS One 2011; 6: e21632 [PMID: 21738740 DOI: 10.1371/journal.pone.0021632]
    • (2011) PLoS One , vol.6 , pp. e21632
    • Oikonomou, E.1    Koc, M.2    Sourkova, V.3    Andera, L.4    Pintzas, A.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.